Recent Quotes
My Watchlist
Indicators
OGJ 150 Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

427.15 +0.39 (+0.09%)
Streaming Delayed Price Updated: 9:32 AM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
68 69 Next >
News headline image
3 Fantastic Growth Stocks to Buy in August ↗
These stocks should keep up their winning ways. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
3 Biotech Stocks to Buy on the Dip: August 2024 ↗
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning. 
Via InvestorPlace
News headline image
Prediction: These 4 Future Technologies Will Be Millionaire-Makers -- and Here Are the Top Stocks to Buy Now to Profit From Them ↗
These technologies could be game-changers. And they could make forward-thinking investors a lot of money. 
Via The Motley Fool
News headline image
2 Biotech Stocks to Buy Hand Over Fist in August ↗
Both of these biotechs are highly innovative companies. 
Via The Motley Fool
News headline image
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
Vertex Slumps On Light Second-Quarter Despite Hiked 2024 Outlook ↗
The company's sales came in a hair light with losses wider than expected. 
Via Investor's Business Daily
News headline image
14 Analysts Assess Vertex Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
The 3 Best Biotech Stocks to Buy in August 2024 ↗
These biotech stocks are leading the way with groundbreaking therapies and robust fundamentals offering superb upside ahead. 
Via InvestorPlace
News headline image
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
From Vertex Pharmaceuticals
Via Business Wire
News headline image
Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗
Shares of the rare disease drugmaker are already up more than 40% over the past year. 
Via The Motley Fool
News headline image
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030 ↗
Great companies are found in every type of market landscape. 
Via The Motley Fool
News headline image
3 Biotech Stocks on Track for 50% Returns (or More) by 2028 ↗
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace
News headline image
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
News headline image
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker ↗
The biotech recently became a commercial-stage company. 
Via The Motley Fool
News headline image
3 Unstoppable Stocks to Buy in August ↗
It's not hard to envision how all three of these stocks can deliver exceptional growth. 
Via The Motley Fool
News headline image
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now ↗
These two healthcare companies have far more upside potential than Johnson & Johnson. 
Via The Motley Fool
News headline image
3 Biotech Stocks That Could Have Investors Grinning Soon ↗
Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential. 
Via InvestorPlace
News headline image
Magnificent 7 Lose Over $300B As Volatility Index Surges, Traders Question Fed's Timing: What's Driving Markets Friday? ↗
Wall Street is experiencing a sharp decline on the last trading day of the week, with all indices in the red at noon in New York, as a cooler-than-expected July jobs report rattled risk sentiment and... 
Via Benzinga
Topics Economy
News headline image
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline ↗
Vertex Pharmaceuticals reported Q2 revenues of $2.65B, near the $2.66B estimate, with an adjusted EPS loss of $(12.83), missing the $4.14 consensus. The analyst expects strong growth in the pain... 
Via Benzinga
News headline image
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second. ↗
Vertex's first loss in years is a big nothingburger. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals (VRTX) Q2 2024 Earnings Call Transcript ↗
VRTX earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Reports Second Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Got $500? 2 Compelling Growth Stocks to Buy and Hold Forever ↗
These businesses are looking like increasingly attractive buys. 
Via The Motley Fool
News headline image
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday? ↗
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market... 
Via Benzinga
News headline image
The Top 3 Biotech Stocks to Buy Now Summer 2024 ↗
These biotech stocks are well-positioned to generate high returns for investors due to their significant growth prospects. 
Via InvestorPlace
News headline image
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November ↗
After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a... 
Via Benzinga
News headline image
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame? ↗
DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now. 
Via The Motley Fool
News headline image
The Top 3 Cathie Wood Stocks to Buy Now: Summer 2024 ↗
The investing guru likes to take the pulse of where the world will be tomorrow and these Cathie Wood stocks reflect that vision. 
Via InvestorPlace
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>